Numbers

“Nanolek” entered Russia’s top 50 fastest growing companies

RBC rating ↗

About

19.5

billion rubles

the company's turnover in 2021

64

%

the average

annual rate of growth in 2017-2021

200

million

tablets have been produced since 2014 — enough to lay a road from Kirov to the “Vostok” Antartic station

15

million

children in Russia have already been immunized with vaccines produced by “Nanolek”

Plant

At the innovative Nanolek Plant in the Kirov region medicines are produced according to international GMP* and ISO 9001 standards**

Drugs for the treatment of cancer

Bavencio

Bavencio

Avelumab — Human Immunoglobulin Gl, Monoclonal antibody

Darzalex

Darzalex

Daratumumab is a monoclonal antibody that acts on the CD38 surface protein

Neupomax

Neupomax

Filgrastim — recombinant human granulocyte colony stimulating factor

Stibevara

Stibevara

Bevacizumab is a recombinant hyperchymeric monoclonal IgG1 antibody

Tretinoin

Tretinoin

Tretinoin

Drugs for the treatment of orphan diseases

Hunterase

Hunterase

Iduronate-2-sulfatase is a drug for enzyme replacement therapy for Hunter syndrome

Fabrazyme

Fabrazyme

Agalsidase beta — enzyme for the treatment of Fabry's disease

R&D

Nanolek’s own R&D centre by the same name was opened in 2021 in the science city of Pushchino with the goal of developing new medicines there from scratch.

r&d

The path of a drug from a molecule to market entry takes up to 6 years. Early development of development of a single molecule takes 1-2 years. Furthermore, on average only 10 out of 100 hypotheses of molecules make it to market.

The Nanolek R&D Center operates on the basis of the Pushchinsky Institute of Biological Instrumentation of the Russian Academy of Sciences. These scientists focus on new methods and technologies in physico-chemical biology, medicine, and pharmacology.